Biogen Inc. (BIIB)
$228.90-0.22%Close
BUYBULL · day 19
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV17.4%–65.9%
- Market cap
- $33.8B
- Beta
- 0.17
- P/E (TTM)
- 40.30
- IV-%ile
- 38
- IV ATM
- 31.5%
- Short % float
- 4.08%
- Days to cover
- 4.9
- SI change
- +2.5%
- 1W
- +2.70%
- 1M
- +5.31%
- vs SPY 1W
- +2.84%
- vs SPY 1M
- +2.80%
Industry peers
FMP comparable companies · ranked by market cap
- LLYBUYEli Lilly and Company$1.1TRECOVERYQ 21$1179.27-1.36%
- AZNSELLAstraZeneca PLC$246.9BRECOVERYQ 20$159.20-1.59%
- AMGNBUYAmgen Inc.$223.9BRECOVERYQ 22$414.87-1.13%
- PFESELLPfizer Inc.$161.2BBULLQ 13$28.28-0.11%
- VRTXSELLVertex Pharmaceuticals Incorporated$129.5BBEARQ 23$510.08-4.30%
- REGNSELLRegeneron Pharmaceuticals, Inc.$76.9BBEARQ 24$746.54-1.27%
- ALNYSELLAlnylam Pharmaceuticals, Inc.$31.1BRECOVERYQ 28$232.68-1.41%
- UTHRBUYUnited Therapeutics Corporation$23.3BRECOVERYQ 20$549.16-1.22%
- IONSSELLIonis Pharmaceuticals, Inc.$7.5BCRISISQ 8$45.28-2.95%
- PTCTSELLPTC Therapeutics, Inc.$5.4BCRISISQ 18$64.70-4.77%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on BIIB?
- LOPJLB’s latest quantitative signal on Biogen Inc. (BIIB) is BUY in a BULL regime. Signals are updated daily.
- What market regime is BIIB in?
- Biogen Inc. (BIIB) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Biogen Inc. (BIIB) do?
- Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provi…